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Background: Activation of hyaluronic acid (HA) and associated enzyme synthesis has been demonstrated in
experimental stroke animal models. Our study aimed to investigate the plasma levels of HA in acute stroke
patients and the associations between HA levels and functional outcome.
Methods: This was a multicenter case–control study. Acute stroke patients and age- and sex-matched non-stroke
controls were recruited. Plasma levels of HA in acute stroke patients were determined at <48 hours and at 48
to 72 hours after stroke onset by standard ELISA. Favorable functional outcome was defined as modified Rankin
scale ≤2 at 3 months after stroke.
Results: The study included 206 acute stroke patients, including 43 who had intracerebral hemorrhage and 163
who had ischemic stroke, and 159 controls. The plasma levels of HA in the acute stroke patients were significantly
higher than those in the controls (219.7 ± 203.4 ng/ml for <48 hours and 343.1 ± 710.3 ng/ml for 48 to 72 hours
versus 170.4 ± 127.9 ng/ml in the controls; both P < 0.05). For intracerebral hemorrhage patients, HA ≤500 ng/ml
(<48 hours) was an independent favorable outcome predictor (P = 0.016). For ischemic stroke patients, an inverted
U-shaped association between plasma HA (48 to 72 hours) and outcome was noted, indicating that ischemic stroke
patients with too high or too low plasma HA levels tended to have an unfavorable outcome.
Conclusion: HA plasma level was elevated in patients with acute stroke, and can predict 3-month functional outcome,
particularly for patients with intracerebral hemorrhage.
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Stroke is the third major cause of mortality and the leading
cause of permanent disability worldwide [1,2]. Theoretic-
ally, the occurrence of acute stroke would rapidly cause
cell necrosis in the affected core region [3-6]. In the region
surrounding the core of ischemic or hemorrhagic injures,
a series of delayed cellular signaling related to cell apop-
tosis would then induce more cell death and clinical
deterioration [3,7,8]. In the chronic phase, cell repair
and regeneration would determine the ultimate extent
of brain damage and recovery [9,10]. Among various* Correspondence: jsjeng@ntu.edu.tw
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unless otherwise stated.pathophysiologic mechanisms, inflammatory reactions
intrinsic to the central nervous system as well as circu-
lating blood cells are the key elements throughout the
different phases after stroke [11,12]. Previous studies
have suggested that various inflammatory cytokines
(such as tumor necrosis factor-α, interleukin-β, and so
forth) modulate tissue injury in an experimental stroke
model and have potential as important biomarkers in
clinical stroke patients, though their roles in post-stroke
outcome are not completely understood [13-17].
Hyaluronic acid (HA) is a ubiquitous glycosaminoglycan
composed of repeating disaccharide D-glucuronic acid and
N-acetyl-D-glucosamine [18]. It is produced by membrane-
bound enzymes called hyaluronan synthases that form D-
glucuronic acid and N-acetyl-D-glucosamine disaccharidesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Tang et al. Journal of Neuroinflammation 2014, 11:101 Page 2 of 7
http://www.jneuroinflammation.com/content/11/1/101into a polymer [19]. In the other direction, HA is degraded
by hyaluronidase to form oligosaccharides and (very)
low molecular weight HA [20]. HA is distributed widely
throughout connective, epithelial, and neural tissues [21].
HA has various physiological functions, from acting as the
major component of extracellular matrix, cell migration
and proliferation, and wound repair, to endogenous activa-
tion of immunity [21-24]. Recently, there has been more
evidence suggesting that HA degradation products inter-
act directly with toll-like receptors (TLRs) and activate
downstream inflammatory signals [25-27].
Importantly, one study showed that hyaluronidases were
activated and resulted in the generation of HA fragments
in both experimental stroke animal models and human
stroke brain tissues [28]. The same study also showed that
serum levels of HA in acute ischemic stroke (IS) patients
were increased within 1 week after stroke but not asso-
ciated with stroke severity, though the sample size was
small. Moreover, no previous study has focused on the
levels of HA in patients with acute intracerebral
hemorrhage (ICH). In the present study, we measured
the plasma levels of HA in acute stroke patients at two
different time points, less than 48 hours and 48 to
72 hours after stroke onset, and aimed to identify the
associations between HA levels andfunctional outcome.
Materials and methods
Study population
This was a multicenter study involving two medical centers
(National Taiwan University Hospital and Tri-Service
General Hospital) and three community hospitals (National
Taiwan University Hospital Yun-Lin Branch, Taipei
Medical University Hospital and Taipei Medical University
Shuang Ho Hospital). Patients who had acute stroke and
were admitted within 24 hours after stroke onset and
who initially had blood drawn within 48 hours after
stroke onset were recruited. The diagnosis of stroke was
confirmed and characterized by head magnetic resonance
imaging (diffusion-weighted imaging) or repeated com-
puted tomographyscanning (if the first scan did not
clearly demonstrate the infarct region). Patients with
IS or ICH were included. IS was further classified into
five major subtypes according to the Trial of ORG
10172 in Acute Stroke Treatment (TOAST) criteria:
large artery atherosclerosis, small vessel occlusion, cardi-
oembolism, specific etiology, and undetermined etiology
[29]. Patients with a known active infection, cancer,
autoimmune disorder, or current steroid treatment at
the time of blood sampling were excluded. Age- and
sex-matched control subjects free of cardiovascular events
within the previous 12 months were included for compari-
son. This study was approved by the ethics committees
of the participating hospitals including National Taiwan
University Hospital Research Ethics Committee, TaipeiMedical University Joint Institutional Review Board and
Institutional Review Board of Tri-Service General Hospital,
National Defense Medical Center and all patients gave their
written informed consent.
Clinical protocol
For the acute stroke patients, blood samples were drawn
at two time points: within 48 hours and 48 to 72 hours
after the onset of stroke. A single sample of blood was
taken from each control subject. In our study protocol,
blood sampling was performed with at least 18 hours or
1 working day between the time points for the < 48 hours
and 48 to 72 hours sample. A detailed history of clinical
presentation, vascular risk factors and co-morbidity was
obtained from each patient. Medications for diabetes
mellitus, hypertension and hyperlipidemia were reviewed
and recorded. Body mass index was calculated as weight
divided by the square of height. Stroke severity at admis-
sion was assessed by the National Institutes of Health
Stroke Scale (NIHSS). Mortality and functional outcome
3 months after stroke onset were determined. Favorable
outcome was defined as a modified Rankin Scale score
of ≤2. Complete blood cell counts and biochemistry
were performed at the time of admission.
Human plasma collection and measurements
Ten-milliliter samples of blood drawn from the controls
and stroke patients were decanted into EDTA tubes,
then centrifuged at 300 g for 15 minutes, aliquoted into
1.5-ml tubes and stored at −80°C until used. The plasma
levels of HA were determined using a commercially
available ELISA kit (Hyaluronan Enzyme-Linked Immuno-
sorbent Assay Kit, Echelon Biosciences Inc., Salt Lake
City, UT, USA) and no cross reaction to other protein
was mentioned according to the manufacturer’s protocol.
Measurements were performed in duplicate and the
results were averaged. Samples with obvious hemolysis
which was visually detected by observing a pink to red
tinge inside were not used for measurements.
Statistical analysis
Statistical analysis was performed using R 2.14.1 software
(R Foundation for Statistical Computing, Vienna, Austria).
A two-sided P value ≤0.05 was considered statistically
significant. The distributional properties of continuous
variables were expressed as the mean ± standard devi-
ation, whereas categorical variables were represented as
frequency and percentage. Forunivariate analysis, the
differences in the clinical and biochemical parameters
between good and poor outcomes were analyzed using the
chi-square test, Fisher’s exact test, the two-sample t test,
one-way analysis of variance, the Wilcoxon rank-sum test,
the Kruskal-Wallis test, or the log-rank test as appropriate.
Next, multivariate analysis was conducted using fitting
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able selection method to estimate the prognostic effects.
Generalized additive models (GAM) were applied to detect
nonlinear effects of continuous covariates or to discretize
them. Importantly, patients with incomplete biochemistry
data (n = 3) or missing HA data at either time point (n = 2)
were excluded for GAM assay.
Results
Plasma levels of hyaluronic acid in acute stroke patients
A total of 206 acute stroke patients (ICH 20.7%) were
recruited. The basic characteristics of the study partici-
pants are shown in Table 1. Compared with the controls,
acute stroke patients had higher HA plasma levels, espe-
cially at 48 to 72 hours after stroke onset (219.7 ± 203.4
for <48 hours and 343.1 ± 710.3 for 48 to 72 hours versus
170.4 ± 127.9 ng/ml in controls, P = 0.038 and <0.001,
respectively). In consideration of stroke subtypes, IS pa-
tients were significantly older and had a higher percentage
of diabetes mellitus, hypertension and medical treatment
for diabetes mellitus than ICH patients. However, both
ICH and IS patients had significantly higher HA plasma
levels at 48 to 72 hours than at <48 hours post-stroke (all
P < 0.0001), with the higher levels being more pronounced
for ICH patients (P = 0.028 compared to IS at 48 to
72 hours).
Plasma levels of hyaluronic acid (<48 hours) predicts
outcome in intracerebral hemorrhage patients
In ICH patients, univariate analysis showed that patients
with favorable outcome (n = 23, 53.5%) were younger,
had higher body mass index values, and lower NIHSS





Age (years) 62.7 ± 7.5 64.3 ±
Male 90 (56.6) 139 (6
Body mass index (kg/m2) 25.7 ± 4.1 25.4 ±
Diabetes mellitus 77 (48.4) 77 (37
Hypertension 95 (59.7) 158 (7
Hyperlipidemia 40 (25.2) 62 (30
Medication for:
Diabetes mellitus NA 58 (28
Hypertension NA 113 (5
Hyperlipidemia NA 28 (13
HA <48 hours (ng/ml)
HA 48 to 72 hours (ng/ml)
Values are shown as number (percentage) or mean ± standard deviation. HA, hyalur
*P < 0.05 versus ICH.HA plasma levels tended to be lower in patients with fa-
vorable outcome at <48 hours and 48 to 72 hours
(P = 0.06 and 0.08, respectively).
Importantly, GAM identified a cutoff value of HA ≤
500 ng/ml at <48 hours after stroke onset in reference to
a favorable outcome after adjustment for NIHSS score,
diabetes mellitus and age (Figure 1A). Multivariate ana-
lysis showed that plasma HA ≤500 ng/ml at <48 hours
can significantly predict a favorable outcome at 3 months
after ICH (P = 0.016) when adjusted for age, body mass
index, and NIHSS score.
Inverted U-shaped relationship between plasma
hyaluronic acid (48 to 72 hours) and outcome in ischemic
stroke patients
There were 91 (55.5%) IS patients with anterior circulation
infarction; the others (n = 72) had posterior circulation
infarction. Univariate analysis showed that variables
correlated with favorable outcome included younger
age, male gender, lower NIHSS score and white blood
cell count at admission, no history of hypertension and
no history of stroke (Table 2). Similarly to ICH, HA
plasma levels tended to be lower in IS patients with a
favorable outcome at 48 to 72 hours (P = 0.053). With
regard to IS subtypes based on the TOAST classification,
patients with cardioembolism had significantly higher
NIHSS scores and higher HA levels (48 to 72 hours)
than patients with all the other subtypes (Table 3).
Although multivariate analysis did not show an inde-
pendent effect of HA plasma levels at either <48 hours or
48 to 72 hours in predicting outcome, GAM demon-
strated an inverted U-shaped relationship between log
transformed HA plasma levels at 48 to 72 hours ande patients
07)
Stroke subtypes
ICH (n = 43) IS (n = 163)
13.8 60.1 ± 14.7 65.4 ± 13.5*
7.1) 28 (65.1) 111 (68.1)
3.8 24.0 ± 3.7 25.7 ± 3.8
.2) 10 (23.3) 67 (41.1)*
6.3) 39 (90.7) 119 (73.0)*
.0) 9 (20.9) 53 (32.5)
.0) 5 (11.6) 53 (32.5)*
4.6) 22 (51.1) 91 (55.8)
.5) 3 (7.0) 25 (15.3)
252.6 ± 188.3 211.0 ± 206.9
554.0 ± 1127.7 287.1 ± 540.7*
onic acid; ICH, intracerebral hemorrhage; IS, ischemic stroke; NA, not available.
Table 2 Comparison by functional outcome for patients with intracerebral hemorrhage and ischemic stroke
Intracerebral hemorrhage Ischemic stroke
mRS ≤2* (n = 23) mRS > 2 (n = 20) P mRS ≤2* (n = 82) mRS > 2 (n = 81) P
Age (years) 54.2 ± 12.9 66.8 ± 13.9 0.004 62.6 ± 14.0 68.3 ± 12.4 0.007
Male 15 (65.2) 13 (65) 1.000 64 (78.0) 47 (58.0) 0.007
Body mass index (kg/m2) 25.1 ± 3.1 22.6 ± 3.8 0.023 25.9 ± 3.8 25.5 ± 3.7 0.528
Diabetes mellitus 8 (34.7) 2 (10.0) 0.076 30 (36.6) 37 (45.7) 0.267
Hypertension 21 (91.3) 18 (90.0) 1.000 53 (64.6) 66 (81.5) 0.021
Hyperlipidemia 3 (13.0) 6 (30.0) 0.263 25 (30.5) 28 (34.6) 0.618
Atril fibrillation 1 (4.3) 1 (5.0) 1.000 17 (20.7) 25 (30.9) 0.155
History of stroke 3 (13.0) 4 (20.0) 0.687 10 (12.2) 26 (32.1) 0.002
WBC (103/μl) 10.2 ± 4.4 10.3 ± 2.8 0.860 8.3 ± 2.8 9.3 ± 4.0 0.050
Hemoglobin 14.9 ± 1.3 13.0 ± 4.4 0.057 14.6 ± 3.7 13.9 ± 1.9 0.173
Glucose (mg/dl) 137.3 ± 59.2 113.5 ± 32.3 0.117 145.5 ± 61.9 148.8 ± 55.8 0.723
Creatinine (mg/dl) 1.2 ± 0.7 1.1 ± 0.4 0.492 1.2 ± 1.0 1.3 ± 0.9 0.356
NIHSS 9.7 ± 5.5 17.6 ± 7.6 <0.001 5.1 ± 5.8 13.1 ± 7.4 <0.001
Systolic blood pressure (mmHg) 184.1 ± 44.5 190.1 ± 38.2 0.640 157.9 ± 31.8 160.8 ± 32.7 0.565
HA < 48 hours (ng/ml) 202.7 ± 134.1 310.1 ± 225.9 0.061 195.9 ± 164.0 226.0 ± 242.6 0.356
HA 48 to 72 hours (ng/ml) 271.1 ± 226.8 879.6 ± 1594.7 0.077 206.1 ± 304.2 379.2 ± 698.0 0.053
Values are shown as number (percentage) or mean ± standard deviation. P values in bold indicate statistical significance. HA, hyaluroninc acid; mRS, modified
Rankin scale; NIHSS, National Institute of Health Stroke Scale; WBC, white blood cell. *Favorable outcome is mRS ≤2 at 3 months after stroke; unfavorable outcome
is mRS > 2 at 3 months after stroke.
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HA(log transformed) between 4.55 and 6.12 ng/ml tend to
have a higher probability of favorable outcome than others
after adjustment for independent clinical parameters in-
cluding NIHSS score, initial glucose levels, sex, history of
dyslipidemia and history of stroke (P = 0.095) (Figure 1B).
Discussion
TLRs and associated downstream signaling in the central
nervous system has been shown to be upregulated in
response to acute ischemic or hemorrhagic strokes [30-34].
Importantly, activation of TLR signaling requires ligands.
Possible candidates of endogenous TLR ligands include
high mobility group box 1 (HMGB1), HA and heat shock-
proteins, and so forth [35]. Our recent work showed that
plasma levels of HMGB1 increased after the onset of IS,
and inhibition of HMGB1 activity via administration of a
recombinant-soluble form of receptor for advanced glyca-
tion end-products significantly improved outcome in a
mouse stroke model [36]. However, data from our IS pa-
tients did not show a significant association between the
plasma levels of HMGB1 and 3-month functional out-
come [36]. One possibility may be the relatively small
sample size in that study. In addition, we did not measure
plasma levels of HMGB1 in ICH patients. Further studies
to compare the correlation between plasma HMGB1 and
HA at the same time points would be interesting.
The current study revealed several important findings.
First, the levels of plasma HA were significantly higherin acute stroke patients than in controls and the levels
increased progressively after stroke. Second, lower levels
of plasma HA at the time point of <48 hours after stroke
with a cutoff level of HA ≤500 ng/ml tended to indicate
a better prognosis in ICH patients. Third, there is an
inverted U-shaped relationship between plasma HA level
at 48 to 72 hours after stroke onset and post-stroke
outcome in IS patients.
Previous studies have shown increased levels of circulat-
ing HA in patients with various diseases, such as septic
shock, thermal injury, rheumatoid arthritis and vasculitis
[37-41]. Most studies showed that HA levels are corre-
lated with an increase in disease severity. These data sup-
port the concept that a systemic inflammatory process
may enhance the production of HA and trigger the associ-
ated immune responses. Elevated plasma HA has been
found to be a marker for the extent of collateral formation
in patients with coronary artery disease [42]. Furthermore,
in our study, IS patients had a higher percentage of med-
ical treatment for diabetes mellitus but not for hyperten-
sion and hyperlipidemia than ICH patients. Whether
medication for cardiovascular diseases would affect the
levels of HA remains uncertain and deserves further
investigation.
For patients with acute stroke, only one previous study
(that included 54 acute IS patients) showed that serum
HA levels increased significantly, with the highest levels
found at 7 days after stroke [28]. However, there was
no obvious association between hyaluronidase activity
Figure 1 Association between plasma levels of hyaluronic acid and post stroke outcome. (A) For intracerebral hemorrhage (ICH) patients,
generalized additive models (GAM) identified a cutoff value of hyaluronic acid (HA) ≤500 ng/ml at <48 hours after stroke onset in reference to a
favorable outcome after adjustment for National Institutes of Health Stroke Scale (NIHSS), diabetes mellitus and age. (B) Incontrast, there was an
inverted U-shaped relationship between log transformed plasma levels of HA at the 48 to 72 hours time point and outcome in ischemic stroke
(IS) patients after adjustment for NIHSS, initial glucose levels, sex, history of dyslipidemia and history of stroke.
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Together with our findings, these results may highlight
the complicated role of HA-mediated inflammatory re-
sponses in the pathogenesis of acute ischemic brain injury.
Looking back at previous relevant studies, acute im-
mune responses were initially recognized as key detri-
mental elements for post-ischemic cell death after stroke.
However, anti-inflammatory therapies did not improve
outcome in clinical settings [43]. Therefore, the finding in
our IS patients of an inverted U-shaped relationship be-
tween plasma HA and outcome may exactly reflect thedilemma that delayed inflammation seems to be a double-
edged sword in post-IS damage and recovery. With re-
spect to IS subtypes, patients with cardioembolism had
significantly higher levels of HA than patients with the
other IS subtypes. They also had higher NIHSS scores
than patients with other IS subtypes. Thus, the differences
in HA levels among different IS subtypes may be related
to the severity of acute stroke rather than the IS subtype.
Compared to IS, research on the role of inflammation
after ICH has been more limited. Available evidence from
preclinical and clinical studies suggest that inflammatory










Age (years) 64.0 ± 12.8 65.0 ± 13.7 68.8 ± 11.9 64.9 ± 15.2
Male 37 (78.7) 31 (74.5) 18 (60.0) 25 (59.5)
Body mass index (kg/m2) 25.4 ± 3.2 26.4 ± 3.9 24.9 ± 3.0 25.9 ± 4.2
Diabetes mellitus 23 (48.9) 16 (36.4) 11 (36.7) 17 (40.5)
Hypertension 33(70.2) 29 (65.9) 23 (76.7) 34 (81.0)
Hyperlipidemia 16 (34.0) 16 (36.4) 5 (16.7) 16 (38.1)
Atril fibrillation 0 (0) 0 (0) 26 (74.1)** 16 (38.1)**
History of stroke 14(30.0) 7(15.9) 9 (30.0) 6 (14.3)
NIHSS 10.9 ± 8.4** 4.7 ± 4.6 14.9 ± 6.2** 7.6 ± 7.6
mRS ≤2 17 (36.2) 29 (65.9)** 9 (30.0) 27 (64.3)**
HA <48 hours (ng/ml) 194.7 ± 186.4 213.4 ± 258.3 258.6 ± 191.5 192.2 ± 178.3
HA (ng/ml) 48 to 72 hours (ng/ml) 218.8 ± 270.41 189.5 ± 260.8 508.4 ± 879.8* 316.2 ± 644.7
Values are shown as number (percentage) or mean ± standard deviation. HA, hyaluronic acid; mRS, modified Rankin scale; NIHSS, National Institute of Health
Stroke Scale; Others, specific etiology, and undetermined etiology in TOAST classification; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
The values of all pairs of columns were compared to each other.*P < 0.05, **P < 0.01.
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and recovery in ICH, though the importance of their
contribution to post-stroke outcome is still uncertain
[17]. In our study, the linear association between plasma
levels of HA (<48 hours) and outcome in ICH patients
leads to the detrimental implication of the immune re-
sponse in the pathogenesis of post-ICH brain damage.
There are several study limitations. First, acute stroke
could trigger primary inflammation in the affected brain
region and secondary systemic inflammation. Thus, it is
unclear whether our measured plasma HA levels were
influenced predominantly by the central nervous system
or systemic systems. Second, the functions of HA could
be diverse, based on the molecular weights of HA and
the activities of hyaluronidase [21]. The results from our
analytic method (ELISA) showed the total amount of
plasma HA rather than the HA within a specific range
of molecular weights. Whether this factor can have a
large effect on the interpretation of our results remains
to be determined by further investigation. However, so
far there is no clinically useful way to quantify a specific
range of plasma HA levels in human subjects. The last
limitation is that the sample size of ICH patients was
relatively small, though the results were statistically
significant. Further studies with larger sample sizes are
necessary to strengthen our findings.
In conclusion, our study provided evidence of activation
of HA synthesis in acute stroke and identified the diverse
patterns of association between plasma HA levels and
outcome in patients with IS and ICH. Furthermore,
levels of HA after stroke can help predict functional
outcome, especially in ICH patients.Abbreviations
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hemorrhage; IS: ischemic stroke; NIHSS: National Institutes of Health Stroke Scale;
TLR: toll-like receptor; TOAST: Trial of ORG 10172 in Acute Stroke Treatment.
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